Educational implementation research directed at empowering patients, care givers and physicians.
Not Applicable
- Conditions
- Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue
- Registration Number
- CTRI/2024/02/062504
- Lead Sponsor
- Pfizer Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients diagnosed with inflammatory arthritis such as Rheumatoid arthritis (RA)and Spondyloarthritis(SpA)
Primary health care providers involved in care of such patients
Exclusion Criteria
Non-immune mediated arthritis such as gout, osteo-arthritis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method We expect to achieve more than 80 percent improvement in medication-adherence and treat to target outcomes in arthritis patients as dictated by international guidelines. Through educating primary care providers, we expect to reduce time to diagnosis, treatment initiation and improve rheumatology referrals in inflammatory arthritis (Rheumatoid Arthritis, Spondyloarthritis).Timepoint: 4 months
- Secondary Outcome Measures
Name Time Method A. Develop and implement a scalable and replicable patient education model for hospitals treating AIRDs in low- and middle-income settings. <br/ ><br>B. Access to high quality care irrespective of socioeconomic or cultural setting for patients with AIRDs. <br/ ><br>C. Improve clinical practice with respect to diagnosis and treatment of AIRDs among primary care physicians caring for AIRD patients. <br/ ><br>D. Inform and improve referral services for AIRD patients in remote areas. <br/ ><br>Timepoint: 16 months